BackDNA Print Genomics Overview

DNA Print Genomics Intangible Assets

DNA Print Genomics's intangible assets is $150K.

Get informed when a big investor buys or sells

+ Follow
Intangible Assets
$151409.00

Peer average

Loading

DNA Print Genomics Intangible Assets History

Loading

DNA Print Genomics vs. peers: Intangible Assets Comparison

Loading

DNA Print Genomics Intangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

DNA Print Genomics (DNAG) FAQ

DNA Print Genomics (DNAG) currently reports a intangible assets of $150K as of September 2007. In the prior-year period, the figure was $0. Use the charts on this page to explore DNA Print Genomics's intangible assets history and peer comparisons.

DNA Print Genomics's intangible assets changed from $0 to $150K (period ending September 2007). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

DNA Print Genomics reported $150K in intangible assets as of September 2007. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current intangible assets of $150K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for DNA Print Genomics, and consider following DNAG for alerts when major investors trade the stock.

DNA Print Genomics is classified in the Healthcare sector. On intangible assets, it currently shows $150K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DNAG with unrelated industries.